Hemostasis Rapid Tests and Point of Care (POC) - Medical Devices Pipeline Assessment, 2020
Summary
The publisher's Medical Devices sector report, “Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Hemostasis Rapid Tests & Point of Care (POC) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Hemostasis Rapid Tests & Point of Care (POC) prevent and stop bleeding, meaning to keep blood within a damaged blood vessel (the opposite of hemostasis is hemorrhage).
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Reasons to Buy
The report enables you to -
Summary
The publisher's Medical Devices sector report, “Hemostasis Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Hemostasis Rapid Tests & Point of Care (POC) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Hemostasis Rapid Tests & Point of Care (POC) prevent and stop bleeding, meaning to keep blood within a damaged blood vessel (the opposite of hemostasis is hemorrhage).
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Hemostasis Rapid Tests & Point of Care (POC) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Hemostasis Rapid Tests & Point of Care (POC) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Hemostasis Rapid Tests & Point of Care (POC) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Hemostasis Rapid Tests & Point of Care (POC) - Pipeline Products under Development by Companies
5 Hemostasis Rapid Tests & Point of Care (POC) Companies and Product Overview
6 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Atomo Diagnostics Ltd
- Carclo Diagnostic Solutions Ltd
- Cascade Metrix LLC
- Edan Instruments Inc
- EKF Diagnostics Holdings Plc
- Emosis SAS
- Fraunhofer Institute for Cell Therapy and Immunology
- Helena Laboratories Corp
- Universal Biosensors Inc
![In-Vitro Diagnostics Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach (Lab, POC) - Global Forecast to 2030 - Product Image](http://www.researchandmarkets.com/product_images/12002/12002788_60px_jpg/invitro_diagnostics_market.jpg)
